Table 2.
Area under the effect curve of average rescue medication use
| TA-ER 32 mg N = 324 |
Saline-placebo N = 262 |
TAcs 40 mg N = 212 |
|
|---|---|---|---|
| AUEweeks1–12 | |||
| LSM (SE) | 82.6 (7.81) | 107.1 (8.57) | 103.7 (9.74) |
| LSM difference vs. saline-placebo (p value) | − 24.5 (0.0121) | ||
| LSM difference vs. TAcs (p value) | − 21.1 (0.0424) | ||
| AUEweeks1–24 | |||
| LSM (SE) | 135.6 (13.48) | 187.2 (14.80) | 167.9 (16.82) |
| LSM difference vs. saline-placebo (p value) | − 51.6 (0.0023) | ||
| LSM difference vs. TAcs (p value) | − 32.2 (0.0731) | ||
AUE area under the effect curve, LSM least-squares mean, SE standard error, TAcs triamcinolone acetonide crystalline suspension, TA-ER triamcinolone acetonide extended-release